Exchange Traded Concepts LLC bought a new position in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,175 shares of the company’s stock, valued at approximately $118,000.
Several other large investors have also recently modified their holdings of KURA. BVF Inc. IL increased its stake in Kura Oncology by 77.1% during the 1st quarter. BVF Inc. IL now owns 6,730,983 shares of the company’s stock valued at $82,320,000 after purchasing an additional 2,930,000 shares in the last quarter. Armistice Capital LLC increased its position in shares of Kura Oncology by 15.3% during the first quarter. Armistice Capital LLC now owns 1,236,000 shares of the company’s stock valued at $15,116,000 after acquiring an additional 164,000 shares in the last quarter. Martingale Asset Management L P purchased a new position in Kura Oncology in the 1st quarter worth approximately $522,000. PAX Financial Group LLC lifted its position in Kura Oncology by 15.6% in the 2nd quarter. PAX Financial Group LLC now owns 52,429 shares of the company’s stock valued at $555,000 after acquiring an additional 7,062 shares in the last quarter. Finally, Inspire Investing LLC purchased a new stake in Kura Oncology during the 1st quarter valued at $302,000.
Wall Street Analyst Weigh In
KURA has been the subject of several recent analyst reports. Bank of America began coverage on Kura Oncology in a research note on Friday, August 11th. They issued a “buy” rating and a $31.00 price target for the company. Scotiabank started coverage on shares of Kura Oncology in a research note on Thursday, July 27th. They set a “sector perform” rating and a $10.50 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price target on shares of Kura Oncology in a research note on Thursday, September 7th. Finally, StockNews.com initiated coverage on Kura Oncology in a research report on Thursday, October 5th. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $25.93.
Kura Oncology Stock Performance
NASDAQ:KURA opened at $9.03 on Wednesday. The stock has a 50-day moving average price of $9.92 and a 200 day moving average price of $10.95. The stock has a market capitalization of $670.39 million, a P/E ratio of -4.40 and a beta of 0.78. Kura Oncology, Inc. has a 12-month low of $7.93 and a 12-month high of $17.27. The company has a current ratio of 20.32, a quick ratio of 20.32 and a debt-to-equity ratio of 0.02.
Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.04. Equities research analysts forecast that Kura Oncology, Inc. will post -2.18 EPS for the current fiscal year.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.
Featured Stories
- Five stocks we like better than Kura Oncology
- Best Restaurant Stocks to Invest in Now
- 5 Reasons Gilead Sciences is a Better Buy Than You Think
- Where to Find Earnings Call Transcripts
- Jobs Are Going To The Construction Industry, Momentum Play Time
- How to Use Stock Screeners to Find Stocks
- PepsiCo Q3 Strength Results In A Trend Following Buy Signal
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
